Pharmafile Logo
Pharmafocus logo
Advanced Search

Biogen

Showing 15 posts of 112 posts found.

robina-weermeijer-so1l3jsdd3y-unsplash_2

Eisai shares new data for Leqembi for Alzheimer’s treatment

October 26, 2023
Research and Development Alzheimer's, Biogen, Eisai, Neurology, lecanemab

Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL injection for intravenous (IV) use …

News

Biogen’s biosimilar Tofidence approved by FDA

October 2, 2023
Medical Communications Actemra, Biogen, FDA, Musculo-skeletal disorder, Tofidence

Biogen has announced that the US Food and Drug Administration (FDA) has approved Tofidence (tocilizumab-bavi) as an intravenous formulation, a …

News
money_pills_2

Biogen to acquire Reata Pharmaceuticals

July 31, 2023
Business Services Biogen, Neurology, Reata Pharmaceuticals, acquisition

Biogen and Reata Pharmaceuticals have announced that they have entered a definitive agreement under which Biogen will acquire Reata for …

News
Alzheimer's brain

FDA grants Alzheimer’s disease drug Leqembi full approval

July 7, 2023
Medical Communications Alzheimer's disease, Biogen, Eisai, FDA, Neurology

Japanese pharmaceutical company Eisai and US-based biotechnology company Biogen have announced that the US Food and Drug Administration (FDA) has …

News

Biogen Phase III choroideremia study did not meet primary endpoint

June 15, 2021
Manufacturing and Production Biogen, choroideremia, phase III

Biogen has announced that its investigational gene therapy study for the potential treatment of choroideremia did not meet its primary …

News
biogen_austria_238

Biogen fails to meet primary endpoint in XLRP study

May 17, 2021
Sales and Marketing Biogen, Clinical Trail

Biogen have released topline results from its Phase2/3 Xirius study of cotoretigene toliparvovec (BIIB112) as a gene therapy for patients …

News
dw-anzcxqaqavhl

FDA approves new IM administration route for Biogen’s MS drug Plegridy

February 2, 2021
Manufacturing and Production Biogen, MS

The FDA has approved a new intramuscular (IM) injection route of administration for Biogen’s Plegridy (peginterferon beta-1a) for the treatment …

News
boehringer_biberach_germany_copy

Researchers and pharma companies partner to investigate new schizophrenia treatment

January 21, 2021
Biogen, Boehringer Ingelheim

The University of Oxford, the Earlham Institute, and global pharmaceutical companies Biogen and Boehringer Ingelheim are partnering to investigate a …

News
european_commission_web

Biogen’s IM Plegridy gets EU approval

January 6, 2021
Research and Development Biogen, multiple sclerosis

The European Commission has approved Biogen’s Plegridy (peginterferon beta-1a), a new intramuscular (IM) injection for the treatment of relapsing-remitting multiple …

News
biogen

Biogen agrees to pay $22m to settle kickback allegations

December 18, 2020
Medical Communications Biogen, multiple sclerosis

Biogen has agreed to pay $22 million to put an end to an investigation into claims that it illegally used …

News
glenmark

FDA greenlights Glenmark’s generic version of Biogen’s Tecfidera in relapsing multiple sclerosis

October 7, 2020
Research and Development, Sales and Marketing Biogen, Glenmark, generic, multiple sclerosis

Glenmark Pharma will be celebrating after it secured FDA approval in the US to market dimethyl fumarate, a generic version …

News
biogen-idec-tecfidera-dimethyl-fumarate

Mylan secures first FDA approval for generic version of Biogen’s Tecfidera following patent dispute

August 20, 2020
Sales and Marketing Biogen, FDA, Mylan, generic, tecfidera

The FDA has approved its first generic of Biogen’s multiple sclerosis (MS) treatment Tecfidera, awarding authorisation to Mylan which is …

News
nhs_sign_8

Scottish Medicines Consortium approves new drugs in multiple sclerosis, ulcerative colitis and diabetes

April 15, 2020
Research and Development, Sales and Marketing Biogen, Fambyra, Janssen, NHS, Rimzoic, Sandoz, Sanofi, Scotland, Scottish Medicines Consortium, Stelara, Suliqua, pharma

Medical regulation must still continue even in a global pandemic, and the Scottish Medicines Consortium, (SMC) has ploughed on with …

News
biogen_austria_238

100 coronavirus cases linked to Biogen-hosted event in Boston, State of Massachusetts confirms

March 18, 2020
Manufacturing and Production, Medical Communications, Research and Development Biogen, coronavirus, pharma

It is now known that around 100 of the known cases of the COVID-19 coronavirus can be traced to an …

News
cambridge_skyline

Biogen and Takeda forced to send employees home as coronavirus hits Massachusetts

March 9, 2020
Manufacturing and Production, Medical Communications Biogen, Takeda, coronavirus, pharma

Big pharma has been hit by the coronavirus (COVID-19) outbreak right on its doorstep, as two of the biggest names …

News

Latest content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024